Author:
Thole Theresa,Eggert Angelika
Publisher
Springer International Publishing
Reference139 articles.
1. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM, Children’s Oncology G. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324–34. https://doi.org/10.1056/NEJMoa0911123.
2. Berlanga P, Canete A, Castel V. Advances in emerging drugs for the treatment of neuroblastoma. Expert Opin Emerg Drugs. 2017;22(1):63–75. https://doi.org/10.1080/14728214.2017.1294159.
3. Castel V, Canete A, Navarro S, Garcia-Miguel P, Melero C, Acha T, Navajas A, Badal MD. Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results. Med Pediatr Oncol. 2001;37(6):537–42. https://doi.org/10.1002/mpo.1248.
4. London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL, Iehara T, Matthay KK. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. 2011;29(24):3286–92. https://doi.org/10.1200/JCO.2010.34.3392.
5. Moreno L, Pearson AD, Guo D, Morgenstern D, Pasqualini C, Ash S, Valteau-Couanet D, Cohn S, London WB. Predicting “early” relapse/progression/death in children with INRGSS stage M neuroblastoma using clinical and biologic factors: an INRG database analysis. Cairns, QL: Paper presented at the Advances in Neuroblastoma Research Congress ANR; 2016.